Skip to main content

Advertisement

SpringerLink
Log in

Induction of clinical remission with adalimumab–methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection

  • Case Report
  • Published:
Modern Rheumatology

Abstract

The patient described here is a 49-year-old woman who had hepatitis C virus (HCV) infection and rheumatoid arthritis (RA). Her RA had been successfully managed with methotrexate for about 10 years. After a sustained virological response was achieved with interferon therapy, treatment with adalimumab was instituted. This resulted in a rapid and sustained remission that lasted for more than a year, without HCV reactivation. The results in this case suggest that a sequential strategy, with initial HCV clearance followed by the targeting of remission with biologics, may be a favorable option in patients with RA and concomitant HCV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon α and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006;7:451–6.

    PubMed  CAS  Google Scholar 

  2. Kötter I, Hamuryudan V, Öztürk ZE, Yazici H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol. 2010;22:278–83.

    Article  PubMed  Google Scholar 

  3. Passos de Souza E, Teles Evangelista Segundo P, Freire José F, Lemaire D, Santiago M. Rheumatoid arthritis induced by α-interferon therapy. Clin Rheumatol. 2001;20:297–9.

    Article  PubMed  CAS  Google Scholar 

  4. The Japan Society of Hepatology. 2007 guidelines for the treatment of chronic hepatitis. Tokyo: The Japan Society of Hepatology; 2007.

  5. Sakamoto S, Okanoue T, Itoh Y, Takami S, Yasui K, Kagawa K, et al. Virological and clinico-pathological studies of 2nd anti-HCV positive individuals showing normal liver tests. Kanzo. 1994;35:580–6.

    Article  Google Scholar 

  6. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.

    Article  PubMed  CAS  Google Scholar 

  7. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.

    Article  PubMed  CAS  Google Scholar 

  8. Yamamoto S. Epidemiology of rheumatoid arthritis. Rheumatology (Tokyo). 2000;24:213–21.

    Google Scholar 

  9. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. Intervirology. 2004;47:32–40.

    Article  PubMed  Google Scholar 

  10. Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999;44:563–7.

    Article  PubMed  CAS  Google Scholar 

  11. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52.

    PubMed  Google Scholar 

  12. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    Article  PubMed  CAS  Google Scholar 

  13. Nissen MJ, Fontanges E, Allam Y, Zoulim F, Trépo C, Miossec P. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005;44:1016–20.

    Google Scholar 

  14. The Japan College of Rheumatology 2011 guidelines on the use of methotrexate for rheumatoid arthritis in Japan. Japan College of Rheumatology Group for the Development of Guidelines on the Use of methotrexate (MTX). Tokyo: Yodosha; 2011. p. 16-7.

  15. The Ministry of Health, Labour and Welfare 2011 guidelines for the treatment of chronic hepatitis C. 2011. http://www.jsh.or.jp/medical/documents/HVC1-7.pdf.

  16. Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–22.

    Article  PubMed  CAS  Google Scholar 

  17. Cansu DÜ, Kaļifoğlu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008;35:421–4.

    PubMed  CAS  Google Scholar 

  18. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol. 2010;22:443–50.

    Article  PubMed  CAS  Google Scholar 

  19. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(Suppl II):ii18–24.

    Article  PubMed  CAS  Google Scholar 

  20. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944–9.

    PubMed  CAS  Google Scholar 

  21. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28:787–91.

    Article  PubMed  CAS  Google Scholar 

  22. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16–23.

    Article  PubMed  CAS  Google Scholar 

  23. Calabrese LH, Zein N. Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol. 2007;3:422–3.

    Article  PubMed  CAS  Google Scholar 

  24. Reimold A, Palmer BF. Viruses and arthritis: new challenges in diagnosis, therapy, and immunization. Am J Med Sci. 2010;339:549–56.

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Gennoki Clinic, 2680-1 Nishiharuchika, Ina, Nagano, 399-4431, Japan

    Osamu Noguchi

  2. Gibo Gastroenterology and Internal Medicine Clinic, Chikuma Building 2F, 237 Yoshikawamurai-cho, Matsumoto, Nagano, 399-0032, Japan

    Yukio Gibo

Authors
  1. Osamu Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukio Gibo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Noguchi.

About this article

Cite this article

Noguchi, O., Gibo, Y. Induction of clinical remission with adalimumab–methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection. Mod Rheumatol 21, 696–700 (2011). https://doi.org/10.1007/s10165-011-0469-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-011-0469-9

Keywords

Search

Navigation